Abnormal growth of glomerular mesangial cells (GMCs) contributes to the pathophysiology of many types of nephropathy. Because adenosine is an autocrine/paracrine factor that potentially could regulate GMC proliferation and because the extracellular 3Ј,5Ј-cAMP-adenosine pathway (i.e., the conversion of extracellular 3Ј,5Ј-cAMP to 5Ј-AMP and adenosine on the cell surface) could generate adenosine in the biophase of GMC receptors, we investigated the role of the 3Ј,5Ј-cAMP-adenosine pathway in modulating growth [cell proliferation, DNA synthesis ([ , and mitogen-activated protein kinase activity] of GMCs. The addition of exogenous 3Ј,5Ј-cAMP to human GMCs increased extracellular levels of 5Ј-AMP, adenosine, and inosine, and 3-isobutyl-1-methylxanthine (phosphodiesterase inhibitor), 1,3-dipropyl-8-psulfophenylxanthine (ecto-phosphodiesterase inhibitor), and ␣,␤-methylene-adenosine-5Ј-diphosphate (ecto-5Ј-nucleotidase inhibitor) attenuated the increases in adenosine and inosine. Forskolin augmented extracellular 3Ј,5Ј-cAMP and adenosine concentrations, and 2Ј,5Ј-dideoxyadenosine (adenylyl cyclase inhibitor) blocked these increases. Exogenous 3Ј,5Ј-cAMP and forskolin inhibited all indices of cell growth, and antagonism of A 2 [(E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine, KF17837] or A 1 /A 2 (1,3-dipropyl-8-p-sulfophenylxanthine, DPSPX), but not A 1 (8-cyclopentyl-1,3-dipropylxanthine), or A 3 {N-(2-methoxyphenyl)-NЈ-[2-(3-pyridinyl)-4-quinazolinyl]-urea, VUF5574}, adenosine receptors blocked the growth-inhibitory actions of exogenous 3Ј,5Ј-cAMP, but not the effects of 8-bromo-3Ј,5Ј-cAMP (stable 3Ј,5Ј-cAMP analog). Erythro-9-(2-hydroxy-3-nonyl)adenine (adenosine deaminase inhibitor) plus 5-iodotubercidin (adenosine kinase inhibitor) enhanced the growth inhibition by exogenous 3Ј,5Ј-cAMP and forskolin, and A 2 receptor antagonism blocked this effect. In rat GMCs, down-regulation of A 2B receptors with antisense, but not sense or scrambled, oligonucleotides abrogated the inhibitory effects of 3Ј,5Ј-cAMP and forskolin on cell growth. The extracellular 3Ј,5Ј-cAMP-adenosine pathway exists in GMCs and attenuates cell growth via A 2B receptors. Pharmacological augmentation of this pathway could abate pathological glomerular remodeling.
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There is an increasing awareness and consensus that abnormal growth and activity of glomerular mesangial cells (GMCs) importantly participates in the pathophysiology of a wide range of renal diseases (Schlondörff and Banas, 2009) . Therefore, there is intense interest in investigating the pharmacology and biochemistry of autocrine and paracrine factors that regulate the growth of GMCs. In this regard, adenosine, an endogenous nucleoside, may be of considerable importance. Adenosine is involved in regulating multiple physiological systems in the kidney, and these actions of adenosine are mediated by specific subtypes of adenosine receptors (A 1 , A 2A , A 2B , and A 3 receptors) (Vallon et al., 2006) . For this reason and because adenosine is a potent growth inhibitor in both cardiac fibroblasts (Dubey et al., 1997) and vascular smooth muscle cells (Dubey et al., 2000a) , it is conceivable that adenosine also regulates the growth of GMCs. Indeed, experiments with specific adenosine receptor agonists and antagonists, and with antisense oligonucleotides, demonstrate that adenosine inhibits mitogen-induced growth of GMCs via activation of A 2B receptors (Dubey et al., 2005) . Therefore, it is important to investigate the mechanisms that are critical for physiological modulation of adenosine synthesis by GMCs.
It is possible that a mechanism called the 3Ј,5Ј-cAMPadenosine pathway may be involved in adenosine production by GMCs. The 3Ј,5Ј-cAMP-adenosine pathway involves the conversion of 3Ј,5Ј-cAMP to 5Ј-AMP and hence to adenosine by the enzymes phosphodiesterase (PDE) and 5Ј-nucleotidase (5Ј-NT), respectively (Jackson and Dubey, 2001) . The 3Ј,5Ј-cAMP-adenosine pathway may have both intracellular and extracellular arms, i.e., adenosine may be formed within the cell and transported to the extracellular space or it may be formed directly in the extracellular space from extracellular 3Ј,5Ј-cAMP that is transported to the cell surface by multidrug-resistance proteins (Cheng et al., 2010) .
In support of the concept of an extracellular 3Ј,5Ј-cAMPadenosine pathway, treatment of vascular smooth muscle cells and cardiac fibroblasts with exogenous (extracellular) 3Ј,5Ј-cAMP increases 5Ј-AMP, adenosine, and inosine levels, and inhibition of PDE with 3-isobutyl-1-methylxanthine (IBMX) and ecto-PDE with 1,3-dipropyl-8-p-sulfophenylxanthine (DPSPX) blocks these increases (Dubey et al., 1996b (Dubey et al., , 2001a . In addition, in these two cell types, ␣,␤-methyleneadenosine-5Ј-diphosphate [AMPCP; ecto-5Ј-NT inhibitor (Zimmermann, 1992) ] blocks the metabolism of exogenous 3Ј,5Ј-cAMP to adenosine and inosine, but not to 5Ј-AMP (Dubey et al., 1996b (Dubey et al., , 2001a . Together, these findings are consistent with the hypothesis that the extracellular limb of the putative 3Ј,5Ј-cAMP-adenosine pathway is a viable metabolic mechanism for the production of adenosine, at least in vascular smooth muscle cells and cardiac fibroblasts. More recent studies demonstrate the presence of the 3Ј,5Ј-cAMPadenosine pathway in rat ileum (Giron et al., 2008) , in skeletal muscle (Chiavegatti et al., 2008) , and on the intracellular membrane surface of adipocytes (Mü ller et al., 2008) .
Given the fact that GMCs robustly produce 3Ј,5Ј-cAMP (Yao et al., , 2007 Zhu et al., 2006) and adenosine inhibits GMC growth, we decided to test the hypothesis that the extracellular 3Ј,5Ј-cAMP-adenosine pathway regulates GMC growth. To achieve this goal, we examined the effects of exogenous and endogenous 3Ј,5Ј-cAMP on growth in GMCs and investigated whether adenosine biosynthesis was involved in the antimitogenic effects of 3Ј,5Ј-cAMP.
Materials and Methods
Materials. 3Ј,5Ј-cAMP, 2Ј,5Ј-dideoxyadenosine (DDA), ␣,␤-methyleneadenosine-5Ј-diphosphate (AMPCP), 8-bromo-3Ј,5Ј-cyclic monophosphate (Br-cAMP), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), platelet-derived growth factor-BB (PDGF-BB), 5-iodotubercidin (ITUB), 1,3-dipropyl-8-p-sulfophenylxanthine (DPSPX), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 3-isobutyl-1-methylxanthine (IBMX), forskolin (FOR), -urea (VUF5574) were purchased from Sigma-Aldrich (St. Louis, MO). (E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine (KF17837) was procured from Kyowa Hakko Kogyo Co. Ltd., (Sunto, Shizuoka, Japan , and human GMCs in the 5th to 6th passages were used for all experiments. Rat GMCs were isolated and cultured as described (Inoue et al., 1998) , and rat GMCs in the 4th passage were used for the experiments with antisense oligonucleotides.
3,5-cAMP Metabolism and Synthesis Studies. Human GMCs were washed twice with HEPES-buffered Hanks' balanced salt solution and treated with 0.5 ml of Dulbecco's phosphate-buffered saline (PBS) with 25 mM HEPES and 13 mM NaHCO 3 in the presence and absence of various treatments. Extracellular (supernatant) levels of purines were analyzed by high-performance liquid chromatography (HPLC) according to our previously described method (Jackson et al., 1996) . The concentrations of purines in the samples were calculated from a standard curve and normalized to cell number. To ensure that the various treatments caused no toxic effects or cell death, trypan blue exclusion assays were used to evaluate the viability of cells treated in parallel.
Antisense Oligonucleotides for A 2B Receptors. GMCs cultured from rat kidneys, rather than human GMCs, were treated with an antisense oligonucleotide. In a previous study, we showed that the antisense oligonucleotide 5Ј-CTCGTGTTCCAGTGACCAA-3Ј against the rat A 2B receptor effectively down-regulates A 2B receptors in rat GMCs (Dubey et al., 2005) . Therefore, in the experiments with antisense oligonucleotides we used this construct in rat GMCs. Sense (5Ј-TTGGTCACTGGAACACGAG-3Ј) and scrambled (5Ј-GCACGCTCTA-TACTGCATG-3Ј) oligonucleotides were used as controls. 3 H]proline incorporation (index of collagen synthesis), and cell number studies were conducted as described previously (Dubey et al., 2000a) in the absence or presence of the indicated pharmacological treatments. The growth stimulus was either fetal calf serum (FCS; 2.5%) or PDGF-BB (25 ng/ml), and the treatments were coadministered with the growth stimulus daily. Treatment durations were 24 h, 48 h, and 4 days for DNA synthesis, collagen synthesis, and cell number, respectively.
MAPK Activity. PDGF-BB-induced MAPK activity in the cytosolic extracts of human GMCs was quantified by our previously described radioactive method with myelin basic protein as the substrate and [␥ 32 P]ATP (Dubey et al., 2000b) . GMCs were treated with PDGF-BB (25 ng/ml) and the various pharmacological treatments for 24 h before MAPK activity was measured. PDGF-BB was used in these studies, rather than 2.5% FCS, because antisense oligonucleotides are degraded by FCS and the increase in MAPK activity is less variable with PDGF-BB.
Statistics. All growth experiments were performed in triplicates or quadruplicates with three to four separate cultures. Data are presented as mean Ϯ S.E.M. Statistical analysis was performed by using analysis of variance, paired Student's t test, or Fisher's least significant difference test as appropriate. A value of p Ͻ 0.05 was considered statistically significant.
Results
Metabolism of 3,5-cAMP by Human GMCs. As shown in Fig. 1 , left, addition of 3Ј,5Ј-cAMP (30 M) to human GMCs caused a time-related increase in the extracellular levels of 5Ј-AMP, adenosine, and inosine. Compared with GMCs not treated with 3Ј,5Ј-cAMP, the levels of 5Ј-AMP, adenosine, and inosine increased significantly (p Ͻ 0.05 versus vehicle-treated controls) in samples incubated for 1 to 120 min. The metabolism of 3Ј,5Ј-cAMP to 5Ј-AMP, adenosine, and inosine was also concentration-dependent (Fig. 1,  right) . Compared with the untreated controls, 5Ј-AMP, adenosine, and inosine levels were significantly different in GMCs incubated for 60 min with concentrations of 3Ј,5Ј-cAMP equal to or more than 1 M. Compared with adenosine, formation of inosine was observed at lower concentrations (0.01 M) of 3Ј,5Ј-cAMP. The greater increase in inosine compared with adenosine at any concentration of 3Ј,5Ј-cAMP was likely because in the GMC culture system adenosine was converted readily to inosine, whereas inosine was not further metabolized and therefore accumulated. The levels of 5Ј-AMP, adenosine, and inosine were near detection limit in cells not treated with 3Ј,5Ј-cAMP.
The effects of various inhibitors on the metabolism of 3Ј,5Ј-cAMP to purines is shown in Fig. 2 . Compared with human GMCs treated with PBS alone (vehicle), the extracellular (medium) levels of 5Ј-AMP, adenosine, and inosine increased significantly in GMCs treated with 30 M 3Ј,5Ј-cAMP. In vehicle-treated GMCs, the levels (nM/10 6 cells) of 5Ј-AMP and adenosine were near the assay detection limit, whereas the levels of inosine were 42 Ϯ 1.3. In 3Ј,5Ј-cAMP-treated cells, the levels (nM/10 6 cells) of 5Ј-AMP, adenosine, and inosine were 1410 Ϯ 111, 124 Ϯ 3.6, and 328 Ϯ 21, respectively (p Ͻ 0.05 versus vehicle-treated GMCs).
Metabolism of 3Ј,5Ј-cAMP into 5Ј-AMP, adenosine, and inosine was significantly inhibited by IBMX (1 mM; Fig. 2 ), a PDE inhibitor that crosses cell membranes (Beavo and Reifsnyder, 1990 ). The levels of adenosine and 5Ј-AMP were near detection limit in the medium of GMCs treated with IBMX alone and were not significantly increased by 3Ј,5Ј-cAMP (30 M) in GMCs treated with IBMX. Inosine levels were detectable in the media of IBMX-treated cells, and compared with GMCs treated with IBMX alone, the levels were marginally, but significantly, increased in GMCs treated with IBMX plus 3Ј,5Ј-cAMP. However, the increase in inosine levels induced by 3Ј,5Ј-cAMP was markedly attenuated in IBMX-treated cells compared with control cells. Metabolism of 3Ј,5Ј-cAMP to 5Ј-AMP, adenosine, and inosine was also attenuated by a high concentration of DPSPX (0.1 mM; Fig. 2 ). DPSPX is a xanthine that is a nonselective adenosine receptor antagonist at low concentrations (nM) but that inhibits ecto-PDE at high concentrations (micromolar to millimolar) and is restricted to the extracellular compartment so as not to inhibit intracellular PDE (Tofovic et al., 1991) . In GMCs treated with a high concentration of DPSPX alone, the levels of 5Ј-AMP, adenosine, and inosine were near detection limit. Compared with control GMCs treated with 3Ј,5Ј-cAMP (30 M) in the absence of a high concentration of DPSPX, the levels of 5Ј-AMP, adenosine, and inosine were decreased by Ն50% in GMCs treated with 3Ј,5Ј-cAMP plus DPSPX (p Ͻ 0.05), indicating that DPSPX attenuated the metabolism of 3Ј,5Ј-cAMP to 5Ј-AMP, adenosine, and inosine.
Treatment of GMCs with 3Ј,5Ј-cAMP in the presence of the ecto-5Ј-NT inhibitor AMPCP (0.1 mM) prevented the metabolism of 3Ј,5Ј-cAMP to adenosine and inosine, but not to 5Ј-AMP (Fig. 2) . The levels of adenosine and inosine in GMCs treated with AMPCP alone or AMPCP plus 3Ј,5Ј-cAMP were near detection limit, whereas the levels of 5Ј-AMP (nM/10 6 cells) were 471 Ϯ 52 and 4137 Ϯ 253, respectively (p Ͻ 0.05).
No loss in cell viability was observed in cells treated with IBMX, AMPCP, or DPSPX in the absence or presence of 3Ј,5Ј-cAMP, suggesting that the changes in 3Ј,5Ј-cAMP metabolism were caused by inhibition of biochemical pathways and not cell toxicity.
Effects of Exogenous and Endogenous 3,5-cAMP on DNA Synthesis, Cell Proliferation, and Collagen Synthesis in Human GMCs in the Absence and Presence of Adenosine Receptor Antagonists (KF17837, DPSPX, VUF5574, and DPCPX) and Adenylyl Cyclase Inhibitor (DDA). FCS (2.5%) significantly induced DNA synthesis (from 2771 Ϯ 307 to 32,228 Ϯ 1740 dpm/well), collagen synthesis (from 8506 Ϯ 485 to 96,258 Ϯ 1529 dpm/well), and cell proliferation (from 7168 Ϯ 408 to 80,386 Ϯ 1538 cells/well) in growth-arrested human GMCs. Treatment of growth-arrested GMCs with exogenous 3Ј,5Ј-cAMP significantly inhibited FCS-induced growth of GMCs (Fig. 3) . To confirm that the effects of 3Ј,5Ј-cAMP on DNA synthesis, cell proliferation, and collagen synthesis were in part mediated via generation of adenosine, the effects of exogenous 3Ј,5Ј-cAMP were evaluated in the presence and absence of KF17837 [a selective A 2 receptor antagonist (Jacobson and Knutsen, 2001) (Jacobson and Knutsen, 2001) ]. The inhibitory effects of 3Ј,5Ј-cAMP on FCS-induced DNA synthesis, cell proliferation, and proline incorporation were significantly reduced in the presence of both KF17837 (10 nM) and DPSPX (10 nM), but not in the presence of DPCPX (10 nM) or VUF5574 (10 nM) (Fig. 3) . Similar to 3Ј,5Ј-cAMP, treatment of GMCs with Br-cAMP (10 M), a membrane-permeant, nonmetabolizable analog of 3Ј,5Ј-cAMP, inhibited FCS-induced DNA synthesis, collagen synthesis, and cell proliferation. However, in contrast to 3Ј,5Ј-cAMP, the inhibitory effect of Br-cAMP on FCS-induced GMC growth was not reduced by KF17837 or DPSPX (Fig. 3) .
To investigate the potential physiological role of endogenous 3Ј,5Ј-cAMP in regulating GMC growth, the effects of forskolin [agent well known to increase cellular 3Ј,5Ј-cAMP levels (Insel and Ostrom, 2003) ] on FCS-induced DNA synthesis and collagen synthesis were investigated. Similar to 3Ј,5Ј-cAMP, forskolin inhibited FCS-induced DNA and collagen synthesis, and the inhibitory effects of forskolin were significantly attenuated by a low concentration of DPSPX (10 nM) and KF17837 (10 nM), but not DPCPX (10 nM) or VUF5574 (10 nM), suggesting that the inhibitory effects were mediated via A 2 adenosine receptors (Fig. 4A) . To confirm that the inhibitory effects of forskolin were 3Ј,5Ј-cAMP-mediated, the inhibitory effects of these agents were assayed in presence of DDA [adenylyl cyclase inhibitor (Johnson et al., 1989) ]. In the presence of DDA, the inhibitory effects of forskolin on DNA and collagen synthesis were significantly attenuated (Fig. 4A) .
Effects of GMC-Derived 3,5-cAMP on DNA Synthesis in the Absence and Presence of Modulators of Adenosine Levels. Treatment of human GMCs with 3Ј,5Ј-cAMP, forskolin, or EHNA [10 M; elevates endogenous levels of adenosine by inhibiting adenosine deaminase (Ijzerman and Van Der Wenden, 1997)] plus ITUB [0.1 M; increases endogenous adenosine by inhibiting adenosine kinase (Ijzerman and Van Der Wenden, 1997) ], inhibited FCSinduced DNA synthesis. When added together with EHNA and ITUB, the inhibitory effects of 3Ј,5Ј-cAMP and forskolin were significantly enhanced. Furthermore, a low concentra- protein. PDGF-BB-mediated stimulation of MAPK activity was reduced in GMCs pretreated for 24 h with 3Ј,5Ј-cAMP or forskolin (Fig. 5, top) . A low concentration of DPSPX (10 nM), but not DPCPX (10 nM) or VUF5574 (10 nM), attenuated the inhibitory effects of 3Ј,5Ј-cAMP and forskolin on MAPK activity.
Synthesis of 3,5-cAMP and Adenosine in Response to Forskolin in the Presence and Absence of EHNA ؉ ITUB, DDA, DPSPX, DPCPX, and KF17837. To ascertain whether the modulation of the growth effects by forskolin were mediated by 3Ј,5Ј-cAMP-derived adenosine, we assayed the levels of 3Ј,5Ј-cAMP and adenosine in human GMCs treated with the various treatments (Fig. 5, bottom) . Compared with GMCs treated with PBS, the levels of 3Ј,5Ј-cAMP, but not adenosine, increased significantly in the medium of GMCs treated with forskolin and were (nM/10 6 cells) 11.5 Ϯ 6.4 and 224 Ϯ 9.6, respectively. Because extracellular adenosine is rapidly metabolized, we assayed the effects of forskolin in the presence of EHNA ϩ ITUB (blockers of adenosine catabolism). Treatment of GMCs with EHNA ϩ ITUB increased the levels of adenosine and 3Ј,5Ј-cAMP in the me- dium from 5.9 Ϯ 3.36 to 178 Ϯ 20 nM/10 6 cells and 11.5 Ϯ 6.4 to 32 Ϯ 2.41 nM/10 6 cells, respectively. In addition, in the presence of EHNA ϩ ITUB, forskolin increased both 3Ј,5Ј-cAMP and adenosine levels in the medium, and these effects were significantly inhibited in the presence of the adenylyl cyclase inhibitor DDA. The stimulatory effects of forskolin on 3Ј,5Ј-cAMP and adenosine synthesis were not inhibited by a low concentration of DPSPX (10 nM) that antagonizes A 2 receptors but does not block ecto-PDE or by KF17837 (10 nM) (Fig. 5, bottom) , nor by the A 1 or A 3 receptor blockers DPCPX (10 nM) and VUF5574 (10 nM) (not shown).
Modulatory Effects of A 2B Receptor Down-Regulation by Antisense Oligonucleotide on the Inhibitory Effects of Exogenous and GMC-Derived 3,5-cAMP on Growth. Treatment of rat GMCs (in three separate experiments) with 0.5 M antisense, but not sense or scrambled, oligonucleotides to A 2B receptors down-regulated the A 2B receptor by 88 Ϯ 6% (typical Western blot shown in Fig. 6 ). Treatment of rat GMCs with 3Ј,5Ј-cAMP (10 M) or forskolin (10 M) under identical conditions inhibited PDGF-BB-induced growth in GMCs treated with scrambled or sense oligonucleotides, but not in GMCs treated with antisense (Fig. 6 ).
Discussion
Stimulation of adenylyl cyclase increases 3Ј,5Ј-cAMP levels, which could theoretically increase adenosine biosynthesis both intracellularly and extracellularly. Intracellular metabolism of 3Ј,5Ј-cAMP to 5Ј-AMP and 5Ј-AMP to adenosine could be catalyzed by cytosolic PDE and cytosolic 5Ј-NT, respectively, and the adenosine thus formed could reach the extracellular space by way of facilitated transport. However, intracellular formation of adenosine may be diminished by the competition of cytosolic 5Ј-NT and adenylate kinase for 5Ј-AMP. Moreover, any intracellular adenosine formed would not necessarily reach cell surface receptors because transport mechanisms must compete with intracellular adenosine kinase and adenosine deaminase for intracellular adenosine. Therefore, the extracellular limb of the 3Ј,5Ј-cAMP-adenosine pathway may be quantitatively more important because stimulation of adenylyl cyclase causes egress of 3Ј,5Ј-cAMP into the highly localized extracellular space via multidrug resistance protein 4 (Cheng et al., 2010) , and the 3Ј,5Ј-cAMP released onto the cell surface could be efficiently converted to adenosine by ecto-PDE and ecto-5Ј-NT (CD73), an enzyme tethered to the extracellular face of the plasma membrane (Zimmermann, 2006) . Hence, production of adenosine by GMCs via the extracellular 3Ј,5Ј-cAMP potentially could give rise to significant concentrations of adenosine at the cell surface, which would act, in an autocrine/paracrine fashion, on cell-surface A 2B adenosine receptors expressed by GMCs to inhibit GMC growth (Fig. 7) .
The presence of the extracellular 3Ј,5Ј-cAMP-adenosine pathway in GMCs is supported by the observations that exogenous 3Ј,5Ј-cAMP increases extracellular levels of 5Ј-AMP, adenosine, and inosine (metabolite of adenosine) in a time-and concentration-dependent fashion. Because 3Ј,5Ј-cAMP is highly hydrophilic and does not penetrate lipid bilayers, the conversion of exogenous 3Ј,5Ј-cAMP to extracellular adenosine most likely is caused by extracellular metab- olism of 3Ј,5Ј-cAMP. This conclusion is supported by the results with AMPCP and DPSPX because AMPCP inhibits ecto-5Ј-NT but not cytosolic 5Ј-NT (Zimmermann, 2006) , and DPSPX does not penetrate cell membranes (Tofovic et al., 1991) . The ability of these inhibitors to attenuate the conversion of exogenous 3Ј,5Ј-cAMP to extracellular adenosine and its metabolites is strong evidence for an extracellular site of 3Ј,5Ј-cAMP metabolism. Moreover, the ability of AMPCP to increase extracellular 5Ј-AMP levels is consistent with an extracellular site of 3Ј,5Ј-cAMP conversion to 5Ј-AMP. In this regard, if 3Ј,5Ј-cAMP were metabolized to 5Ј-AMP within the cell, inhibition of ecto-5Ј-NT with AMPCP would not prevent the further metabolism of 5Ј-AMP to adenosine and would not cause the accumulation of extracellular 5Ј-AMP. The existence of the extracellular 3Ј,5Ј-cAMP-adenosine pathway in GMCs is also supported by the observation that activation of adenylyl cyclase with forskolin increases extracellular levels of 3Ј,5Ј-cAMP and adenosine and that this effect is inhibited by DDA, a drug that blocks adenylyl cyclase. The current findings also support the hypothesis that in GMCs the extracellular 3Ј,5Ј-cAMP pathway inhibits growth via adenosine activating on A 2 receptors. In this regard, EHNA, which prevents the metabolism of adenosine to inosine, plus ITUB, which inhibits the metabolism of adenosine to 5Ј-AMP, enhance the inhibitory effects of 3Ј,5Ј-cAMP on FCS-induced GMC growth, indicating a role for adenosine. This conclusion is further supported by the findings that the inhibitory effects of exogenous and endogenous 3Ј,5Ј-cAMP on GMC growth are prevented by two different adenosine receptor antagonists, namely KF17837 and DPSPX. The fact that KF17837 and DPSPX (A 2 receptor blockers) antagonize the growth inhibitory effects of 3Ј,5Ј-cAMP, whereas DPCPX and VUF5574 (A 1 and A 3 receptor antagonists, respectively) do not, suggests that the growth inhibitory effects of 3Ј,5Ј-cAMP are mediated via adenosine acting on A 2 receptors. Importantly, neither KF17837, DPSPX, DPCPX, nor VUF5574 interfere with the inhibitory effects of 8-bromo-3Ј,5Ј-cAMP, which is a metabolically stable 3Ј,5Ј-cAMP analog, suggesting that the affects of KF17837 and DPSPX are specifically mediated via antagonism of A 2 receptors and are not caused by nonspecific effects. The findings that forskolin inhibits FCS-induced GMC growth and that these effects are blocked by the adenylyl cyclase inhibitor DDA and the A 2 adenosine receptor antagonists KF17837 and DPSPX further supports the concept that the extracellular 3Ј,5Ј-cAMP-adenosine pathway regulates GMC growth via adenosine acting on A 2 receptors.
There are two subtypes of A 2 receptors, namely A 2A and A 2B . The results of the current study show that down-regulation of A 2B receptors by antisense oligonucleotides prevents the ability of both 3Ј,5Ј-cAMP and forskolin to inhibit GMC growth. Thus, it appears that A 2B receptors are responsible for inhibition of GMC growth by adenosine formed from the extracellular 3Ј,5Ј-cAMP-adenosine pathway. These findings are in full accord with previous work in vascular smooth muscle cells, cardiac fibroblasts, and GMCs showing that inhibition of growth by adenosine is mediated by A 2B receptor (Dubey et al., 1996a (Dubey et al., , 1997 (Dubey et al., , 1998a (Dubey et al., ,b, 2000a (Dubey et al., , 2001b (Dubey et al., , 2005 .
The significance of the present study is that the results demonstrate the concept that sufficient quantities of adenosine are formed by GMCs from the metabolism of exogenous or endogenous 3Ј,5Ј-cAMP to engage A 2B receptors and thereby regulate GMC biology. These experiments provide, therefore, the first evidence that human GMCs express the extracellular 3Ј,5Ј-cAMP-adenosine pathway and that adenosine generated via this pathway inhibits mitogen-induced growth and MAPK activity in GMCs via the A 2B receptor. Although previous studies support the existence of the 3Ј,5Ј-cAMP-adenosine pathway in the renal preglomerular microcirculation (Jackson and Mi, 2000) , the identification of this pathway in human GMCs is of key importance because of the pivotal role of GMCs in the pathophysiology of glomerulopathies such as diabetic nephropathy and hypertension-induced glomerulosclerosis (Kwoh et al., 2006; LeHir and Kriz, 2007) and many other glomerulopathies (Schlondörff and Banas, 2009 ).
